Aethlon Narrows Losses, Boosts Cash Amid Hemopurifier Trial Progress

TL;DR

**AEMD's reduced burn rate and cash injection are positive, but the repeated reverse splits scream desperation for Nasdaq compliance; proceed with extreme caution.**

AI Summary

Aethlon Medical, Inc. (AEMD) reported a net loss of $3,248,958 for the six months ended September 30, 2025, a significant improvement from the $5,378,414 net loss in the same period of 2024. Total operating expenses decreased substantially to $3,302,220 for the six months ended September 30, 2025, down from $5,521,856 in the prior year, driven by reductions in professional fees, payroll, and general and administrative expenses. Cash and cash equivalents increased to $5,853,493 as of September 30, 2025, from $5,501,261 at March 31, 2025, primarily due to $3,744,466 in proceeds from a public offering of common stock. The company is advancing its Hemopurifier device, designated as a 'Breakthrough Device' by the FDA for cancer and life-threatening viral infections, with a Phase 1 oncology trial ongoing in Australia, having treated three participants without serious adverse events. Aethlon canceled its Indian trial to conserve resources and focus on the Australian trial. Two reverse stock splits, 1-for-8 on June 9, 2025, and 1-for-10 on October 16, 2025, were implemented to address Nasdaq's minimum bid price requirement.

Why It Matters

Aethlon's ability to significantly reduce its net loss and increase cash reserves, largely through a public offering, is crucial for its continued operations and clinical development. The ongoing Phase 1 oncology trial in Australia for the Hemopurifier, a 'Breakthrough Device,' represents a key value driver for investors, as successful outcomes could lead to market acceptance and competitive advantage in the immunotherapeutic device space. The company's strategic decision to consolidate trial efforts in Australia and terminate the Indian trial demonstrates a focus on resource efficiency, which could impact employees and future product timelines. However, the repeated reverse stock splits highlight persistent challenges in maintaining Nasdaq listing compliance, signaling potential instability to the broader market and investors.

Risk Assessment

Risk Level: high — Aethlon Medical faces high risk due to its significant accumulated deficit of $(171,203,775) as of September 30, 2025, indicating a history of substantial losses. The company's reliance on financing activities, including a $3,744,466 public offering, to fund operations, coupled with two reverse stock splits (1-for-8 on June 9, 2025, and 1-for-10 on October 16, 2025) to maintain Nasdaq listing, points to ongoing financial instability and potential dilution for existing shareholders.

Analyst Insight

Investors should closely monitor the progress and safety data from Aethlon's Phase 1 oncology trial in Australia, as this is the primary driver for future value. Given the high risk associated with the company's financial history and repeated reverse stock splits, new investors should exercise extreme caution and consider waiting for more definitive clinical milestones and sustained financial stability before investing.

Financial Highlights

debt To Equity

0.27

revenue

N/A

operating Margin

N/A

total Assets

$7,323,090

total Debt

$1,577,113

net Income

-$3,248,958

eps

-$10.65

gross Margin

N/A

cash Position

$5,853,493

revenue Growth

N/A

Key Numbers

• $3,248,958 — Net Loss (for the six months ended September 30, 2025, a decrease from $5,378,414 in 2024)
• $5,853,493 — Cash and Cash Equivalents (as of September 30, 2025, up from $5,501,261 at March 31, 2025)
• $3,744,466 — Proceeds from Common Stock Issuance (net cash provided by financing activities for the six months ended September 30, 2025)
• 761,318 — Common Shares Outstanding (as of November 10, 2025)
• 1-for-10 — Reverse Stock Split Ratio (implemented on October 16, 2025, to address Nasdaq compliance)
• 1-for-8 — Reverse Stock Split Ratio (effected on June 9, 2025)
• $171,203,775 — Accumulated Deficit (as of September 30, 2025, indicating significant historical losses)
• 3 — Participants Treated (in the first cohort of the Phase 1 oncology trial in Australia as of November 3, 2025)
• $3,302,220 — Total Operating Expenses (for the six months ended September 30, 2025, down from $5,521,856 in 2024)
• $144,884 — Stock-based Compensation (for the six months ended September 30, 2025, a decrease from $252,821 in 2024)

Key Players & Entities

• Aethlon Medical, Inc. (company) — registrant of the 10-Q filing
• Hemopurifier (product) — clinical-stage immunotherapeutic device
• FDA (regulator) — U.S. Food and Drug Administration
• Nasdaq Capital Market (market) — exchange where AEMD common stock is listed
• Australia (location) — location of ongoing Phase 1 oncology trial
• CDSCO (regulator) — Indian regulatory agency
• Qualtran (company) — India CRO
• Medanta Medicity Hospital (company) — site for canceled Indian trial
• Galanthus nivalis agglutinin (GNA) (product) — affinity resin in Hemopurifier
• September 30, 2025 (date) — end of the reported quarterly period

FAQ

Risk Factors

• Significant Accumulated Deficit [high — financial]: As of September 30, 2025, Aethlon Medical has an accumulated deficit of $171,203,775. This indicates a history of substantial losses, raising concerns about the company's long-term financial viability and its ability to achieve profitability.
• FDA Approval and Commercialization Uncertainty [high — regulatory]: The company's Hemopurifier device has 'Breakthrough Device' designation from the FDA for cancer and life-threatening viral infections. However, this designation does not guarantee eventual FDA approval or successful commercialization, posing a significant risk to future revenue generation.
• Reliance on Clinical Trial Success [high — operational]: Aethlon's progress is heavily dependent on the success of its ongoing Phase 1 oncology trial in Australia. Any adverse events, delays, or failure to demonstrate efficacy in this trial could severely impact the company's development timeline and investor confidence.
• Need for Future Financing [medium — financial]: Despite recent proceeds from a public offering, the company's substantial operating losses and accumulated deficit suggest a continued need for external financing. Future fundraising efforts may be challenging and could dilute existing shareholders.
• Nasdaq Compliance [medium — regulatory]: The company has implemented two reverse stock splits (1-for-8 on June 9, 2025, and 1-for-10 on October 16, 2025) to meet Nasdaq's minimum bid price requirement. Continued non-compliance could lead to delisting, significantly impacting liquidity and investor confidence.
• Resource Allocation and Trial Strategy [medium — operational]: The decision to cancel the Indian trial to conserve resources and focus on the Australian trial highlights the company's limited resources. This concentration of effort on a single trial increases the risk associated with the overall development program.

Industry Context

Aethlon Medical operates in the highly competitive and innovation-driven biotechnology sector, focusing on novel therapeutic devices. The industry is characterized by long development cycles, significant R&D investment, and stringent regulatory hurdles. Companies like Aethlon often rely on breakthrough technologies and strategic partnerships to advance their pipelines and secure market share.

Regulatory Implications

The 'Breakthrough Device' designation for the Hemopurifier by the FDA presents a significant regulatory pathway, potentially accelerating market entry. However, the company must still navigate rigorous clinical trials and FDA approval processes. Failure to meet regulatory standards or demonstrate safety and efficacy could halt development and commercialization efforts.

What Investors Should Do

1. Monitor clinical trial progress and results closely.
2. Assess the company's cash burn rate and future financing needs.
3. Evaluate the impact of reverse stock splits on share price and liquidity.
4. Consider the long-term commercialization potential of the Hemopurifier.

Key Dates

• 2025-09-30: Six months ended September 30, 2025 financial reporting period — Shows reduced net loss and operating expenses compared to the prior year, with increased cash from a stock offering.
• 2025-10-16: 1-for-10 Reverse Stock Split — Implemented to maintain compliance with Nasdaq's minimum bid price requirement, impacting share count and per-share metrics.
• 2025-06-09: 1-for-8 Reverse Stock Split — Previous action taken to address Nasdaq's minimum bid price requirement, also affecting share count and per-share metrics.
• 2025-03-31: Balance sheet date — Represents the prior period's cash position before the recent stock offering.
• 2024-09-30: Six months ended September 30, 2024 financial reporting period — Provides the comparative period for the current six-month results, showing higher net loss and operating expenses.

Glossary

Accumulated deficit

The total cumulative net losses of a company since its inception, minus any cumulative net income. (Indicates the company's historical unprofitability, with Aethlon having $171,203,775 as of September 30, 2025.)

Breakthrough Device

A designation granted by the FDA to devices that provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases. (Aethlon's Hemopurifier has this designation for cancer and viral infections, suggesting potential for expedited review and market entry.)

Reverse Stock Split

A corporate action in which a company reduces the total number of its outstanding shares by consolidating existing shares into fewer, proportionally more valuable shares. (Aethlon has implemented two reverse stock splits (1-for-8 and 1-for-10) to meet Nasdaq's minimum bid price requirement.)

Operating lease right-of-use asset

An asset representing the right to use an underlying asset for the lease term under an operating lease. (Reflects the company's long-term rental commitments, decreasing from $601,846 to $456,496.)

Stock-based Compensation

Compensation provided to employees in the form of stock options or shares, rather than cash. (Decreased to $144,884 for the six months ended September 30, 2025, from $252,821 in the prior year, contributing to lower operating expenses.)

Year-Over-Year Comparison

For the six months ended September 30, 2025, Aethlon Medical significantly reduced its net loss to $3,248,958 from $5,378,414 in the same period of 2024. This improvement was driven by a substantial decrease in total operating expenses, which fell from $5,521,856 to $3,302,220, primarily due to reductions in professional fees, payroll, and G&A. Cash reserves increased to $5,853,493 from $5,501,261, bolstered by proceeds from a public stock offering. New risks include the ongoing need for Nasdaq compliance following two reverse stock splits.

Key Financial Figures

• $0.001 — t: TITLE OF EACH CLASS COMMON STOCK, $0.001 PAR VALUE TRADING SYMBOL AEMD NAM

Filing Documents

• aethlon_i10q-093025.htm (10-Q) — 585KB
• aethlon_ex3101.htm (EX-31.1) — 9KB
• aethlon_ex3201.htm (EX-32.1) — 5KB
• 0001683168-25-008271.txt ( ) — 3689KB
• aemd-20250930.xsd (EX-101.SCH) — 35KB
• aemd-20250930_cal.xml (EX-101.CAL) — 38KB
• aemd-20250930_def.xml (EX-101.DEF) — 140KB
• aemd-20250930_lab.xml (EX-101.LAB) — 286KB
• aemd-20250930_pre.xml (EX-101.PRE) — 250KB
• aethlon_i10q-093025_htm.xml (XML) — 423KB

FINANCIAL STATEMENTS

FINANCIAL STATEMENTS 4 CONDENSED CONSOLIDATED BALANCE SHEETS AT SEPTEMBER 30, 2025 (UNAUDITED) AND MARCH 31, 2025 4 CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS FOR THE THREE AND SIX MONTHS ENDED SEPTEMBER 30, 2025 AND 2024 (UNAUDITED) 5 CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY FOR THE THREE AND SIX MONTHS ENDED SEPTEMBER 30, 2025 AND 2024 (UNAUDITED) 6 CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE SIX MONTHS ENDED SEPTEMBER 30, 2025 AND 2024 (UNAUDITED) 7 NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) 8 ITEM 2.

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 18 ITEM 3.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 23 ITEM 4.

CONTROLS AND PROCEDURES

CONTROLS AND PROCEDURES 23 PART II. OTHER INFORMATION 24 ITEM 1.

LEGAL PROCEEDINGS

LEGAL PROCEEDINGS 24 ITEM 1A.

RISK FACTORS

RISK FACTORS 24 ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS 25 ITEM 3. DEFAULTS UPON SENIOR SECURITIES 25 ITEM 4. MINE SAFETY DISCLOSURES 25 ITEM 5. OTHER INFORMATION 25 ITEM 6. EXHIBITS 26

SIGNATURES

SIGNATURES 27 2 CAUTIONARY NOTICE REGARDING FORWARD LOOKING STATEMENTS This Quarterly Report on Form 10-Q, or Quarterly Report, contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, or Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, which are subject to the safe harbor created by those sections. We may, in some cases, use words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "will," "would" or the negative of these terms, and similar expressions that convey uncertainty of future events or outcomes to identify these forward-looking and are based upon our current expectations, beliefs, estimates and projections, and various assumptions, many of which, by their nature, are inherently uncertain and beyond our control. Such statements, include, but are not limited to, statements contained in this Quarterly Report relating to our business, business strategy, products and services we may offer in the future, the timing and results of future clinical trials, and capital outlook, successful completion of our clinical trials, our ability to raise additional capital, our ability to maintain our Nasdaq listing, U.S. Food and Drug Administration, or FDA, approval of our products candidates, our ability to comply with changing government regulations, patent protection of our proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors detailed herein and in other of our filings with the Securities and Exchange Commission, or the SEC. Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AETHLON MEDICAL, INC. AND SUBSIDIARY CONDENSED CONSOLIDATED BALANCE SHEETS September 30, 2025 March 31, 2025 (Unaudited) ASSETS Current assets Cash and cash equivalents $ 5,853,493 $ 5,501,261 Australian Research and Development Tax Incentive receivable 218,314 – Prepaid expenses and other current assets 182,072 448,539 Total current assets 6,253,879 5,949,800 Property and equipment, net 513,992 676,220 Operating lease right-of-use asset 456,496 601,846 Patents, net 275 550 Restricted cash 98,448 97,813 Deposits – 33,305 Total assets $ 7,323,090 $ 7,359,534 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities Accounts payable $ 570,792 $ 534,524 Due to related parties 248,454 579,565 Operating lease liability, current portion 324,656 313,033 Other current liabilities 261,095 472,164 Total current liabilities 1,404,997 1,899,286 Operating lease liability, less current portion 172,116 336,718 Total liabilities 1,577,113 2,236,004 Stockholders' Equity Common stock, par value $ 0.001 per share; 6,000,000 shares authorized as of September 30, 2025 and March 31, 2025; 761,318 shares issued and outstanding as of September 30, 2025 and 258,531 shares issued and outstanding at March 31, 2025. 761 259 Additional paid-in capital 176,975,368 173,095,221 Accumulated other comprehensive loss ( 26,377 ) ( 17,133 ) Accumulated deficit ( 171,203,775 ) ( 167,954,817 ) Total stockholders' equity 5,745,977 5,123,530 Total liabilities and stockholders' equity $ 7,323,090 $ 7,359,534 The accompanying notes are an integral part of these condensed consolidated financial statements . 4 AETHLON MEDICAL, INC. AND SUBSIDIARY CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS For the Three and Six Month Periods Ended September 30, 2025 and 2024 (Unaudited) Three Months Ended September 30, 2025 Three Months Ended Septemb

View Full Filing

View this 10-Q filing on SEC EDGAR